Gridelli C, Maione P, Amoroso D, Baldari M, Bearz A, Bettoli V, Cammilluzzi E, Crinò L, De Marinis F, Di Pietro F A, Grossi F, Innocenzi D, Micali G, Piantedosi F V, Scartozzi M
Division of Medical Oncology, SG Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy.
Crit Rev Oncol Hematol. 2008 May;66(2):155-62. doi: 10.1016/j.critrevonc.2007.10.004. Epub 2007 Dec 20.
Advances in the knowledge of tumor biology and mechanisms of oncogenesis has granted the singling out of several molecular targets for non-small cell lung cancer (NSCLC) treatment. Among these targets, epidermal growth factor receptor (EGFR), or HER1, has received particular attention in lung cancer treatment. Erlotinib, an orally available inhibitor of EGFR tyrosine kinase in a phase III randomized placebo-controlled trial (BR.21), has been proven to prolong survival in NSCLC patients after first or second line chemotherapy. Skin rash is the most common adverse event associated with erlotinib treatment and it is often cause of negative impact on patients' quality of life. There is no specific treatment for this toxicity due to the lack of evidence-based data and recommendations. A panel of Italian oncologists, who had participated to clinical trials and to the Expanded Access Program for erlotinib in NSCLC treatment, and dermatologists with experience with cutaneous toxicity from EGFR inhibitors, attended a Meeting held in Rome on December 2006 to discuss skin rash from erlotinib and to provide suggestions for managing this frequent side-effect.
肿瘤生物学和肿瘤发生机制知识的进展使得人们能够筛选出几个用于非小细胞肺癌（NSCLC）治疗的分子靶点。在这些靶点中，表皮生长因子受体（EGFR），即HER1，在肺癌治疗中受到了特别关注。厄洛替尼是一种口服的EGFR酪氨酸激酶抑制剂，在一项III期随机安慰剂对照试验（BR.21）中，已被证明可延长NSCLC患者一线或二线化疗后的生存期。皮疹是与厄洛替尼治疗相关的最常见不良事件，并且它常常对患者的生活质量产生负面影响。由于缺乏循证数据和建议，针对这种毒性没有特异性治疗方法。一组参与过NSCLC治疗的临床试验和厄洛替尼扩大使用计划的意大利肿瘤学家，以及有EGFR抑制剂皮肤毒性治疗经验的皮肤科医生，参加了2006年12月在罗马举行的会议，讨论厄洛替尼引起的皮疹，并为处理这种常见副作用提供建议。
